```html

Vulvo‑vaginal Candidiasis

Overview

Vulvo‑vaginal candidiasis (VVC) is a common fungal infection of the female genital tract caused primarily by the yeast Candida albicans. It affects the vulva, vagina, and sometimes the surrounding perineal skin. Although it can occur at any age after puberty, the highest incidence is seen in women of reproductive age (15‑45 years).

Approximately 75 % of women will experience at least one episode of VVC in their lifetime, and about 40‑50 % will have recurrent infections (defined as ≥4 episodes per year). The condition is worldwide and not limited by geography, socioeconomic status, or ethnicity.<sup>[1] CDC, 2023</sup>

Symptoms

Symptoms can range from mild irritation to severe discomfort. Not all women experience every sign.

• Itching and burning – often the first symptom, especially around the vulva and inner thighs.
• Vaginal discharge – thick, white, “cottage‑cheese” consistency; typically odorless.
• Redness and swelling – of the vulva, labia minora, or vestibule.
• Dyspareunia – pain during or after intercourse.
• Urinary irritation – burning sensation during urination due to inflammation of the urethral meatus.
• Vulvar soreness or rawness – may feel like a mild abrasion.
• Increased vaginal discharge after intercourse – friction can exacerbate symptoms.

Causes and Risk Factors

Primary cause

VVC results from an overgrowth of Candida species (most often C. albicans) that normally live in small numbers in the vagina. When the delicate balance of the vaginal microbiome is disturbed, yeast multiplies rapidly, leading to infection.

Major risk factors

• Antibiotic use – broad‑spectrum antibiotics reduce protective lactobacilli.
• Hormonal changes – pregnancy, oral contraceptives, hormone replacement therapy, or a menstrual cycle peak in estrogen.
• Uncontrolled diabetes – higher glucose in vaginal secretions fuels yeast growth.
• Immunosuppression – HIV infection, chemotherapy, corticosteroids, or biologic agents.
• High‑glycemic diet – excess refined sugars may alter vaginal pH.
• Moist, occlusive clothing – tight underwear, synthetic fabrics, or wet bathing suits.
• Sexual activity – while VVC is not classified as a sexually transmitted infection, friction and transmission of yeast between partners can trigger episodes.
• Previous VVC episodes – a history of infection predisposes to recurrence.
• Use of intrauterine devices (IUDs) or spermicides – may affect local flora.

Diagnosis

Accurate diagnosis differentiates VVC from bacterial vaginosis, trichomoniasis, and non‑infectious vulvar skin disorders.

Clinical evaluation

• Detailed history of symptoms, sexual activity, medication use, and underlying medical conditions.
• Physical examination of the vulva and vagina with a speculum to assess discharge, erythema, and lesions.

Laboratory tests

• Microscopy (wet mount) – a saline preparation examined under a microscope to look for budding yeast or pseudohyphae.
• pH testing – vaginal pH is usually ≤4.5 in VVC (higher in bacterial vaginosis or trichomoniasis).
• Culture – agar plates (e.g., Sabouraud dextrose) grown for 48‑72 h to identify Candida species and test antifungal susceptibility, especially in recurrent cases.
• PCR or nucleic‑acid amplification tests (NAATs) – increasingly used for rapid species identification.

Treatment Options

Treatment aims to eradicate the yeast, relieve symptoms, and prevent recurrence.

First‑line antifungal medications

• Azoles (topical) – clotrimazole 1 % cream, miconazole 2 % cream, or tioconazole 6 % ointment applied intravaginally for 3–7 days. Effectiveness >90 %.
• Azoles (oral) – fluconazole 150 mg single dose (most common) or a 3‑day regimen (150 mg daily). Alternatives: itraconazole, voriconazole for resistant strains.

Recurrent vulvo‑vaginal candidiasis (RVVC)

Defined as ≥4 episodes per year. Management often requires a two‑phase approach:

1. Induction phase – treat the acute episode with oral fluconazole 150 mg once weekly for 4 weeks (or daily for 2 weeks).
2. Maintenance phase – low‑dose fluconazole 150 mg weekly for 6 months; some clinicians extend to 12 months.

Adjunct measures (see “Lifestyle changes”) are essential for long‑term control.

Non‑azole alternatives

• Boric acid suppositories (600 mg) – useful for azole‑resistant strains or patients who cannot tolerate azoles.
• Nystatin – topical polyene useful in pregnancy or lactating women.
• Probiotic therapy – oral or vaginal lactobacilli preparations may restore normal flora, though evidence is modest.<sup>[2] Cochrane Review, 2021</sup>

Procedural options

Procedures are rarely needed, but in severe, refractory cases, clinicians may consider:

• Laser or radiofrequency therapy to modify vaginal epithelium (investigational).
• Removal of IUD strings if they appear to act as a nidus.

Lifestyle and supportive measures

• Cold packs or sitz baths with plain water to soothe itching.
• Avoid scented tampons, pads, douches, and soaps.
• Wear breathable cotton underwear; change out of wet clothing promptly.

Living with Vulvo‑vaginal Candidiasis

Even occasional episodes can affect quality of life. Below are practical tips for day‑to‑day management.

Self‑care during an acute episode

• Complete the full antifungal course, even if symptoms improve rapidly.
• Use a gentle, fragrance‑free cleanser; rinse with warm water only.
• Pat dry rather than rub; keep the area dry.
• Consider a loose‑fitting, cotton panty liner (avoid scented or plastic liners).
• Limit sexual activity until symptoms resolve; use condoms to reduce friction.

Managing recurrent infections

• Keep a symptom diary: note timing, triggers (antibiotics, diet, stress), and treatment response.
• Schedule regular follow‑up visits with your gynecologist to review maintenance therapy.
• Control blood glucose if you have diabetes; aim for HbA1c < 7 %.
• Discuss medication interactions with your clinician—fluconazole can affect warfarin, some antidiabetics, and certain antivirals.

Psychosocial aspects

VVC can cause embarrassment or anxiety about sexual intimacy. Open communication with partners and healthcare providers helps reduce stigma. Many support groups and reputable online resources (e.g., CDC’s Women’s Health portal) provide education and reassurance.

Prevention

While occasional episodes are often unavoidable, the following strategies lower the risk of recurrence.

• Maintain vaginal pH – normal pH is 3.8–4.5. Avoid douching, scented hygiene products, and excessive vaginal washing.
• Limit unnecessary antibiotics – only use them when prescribed for a bacterial infection.
• Manage diabetes effectively – regular monitoring and medication adherence.
• Choose appropriate contraception – discuss with your provider if hormonal methods seem to trigger symptoms.
• Wear breathable fabrics – cotton underwear, loose‑fitting clothing, and change out of wet swimsuits within 2 hours.
• Dietary considerations – some evidence suggests reducing refined sugars and high‑glycemic foods may help; focus on a balanced diet rich in vegetables, whole grains, and probiotic foods (yogurt, kefir).
• Probiotic supplementation – daily Lactobacillus rhamnosus GR‑1 and Lactobacillus reuteri RC‑14 have shown modest benefit in preventing recurrence.<sup>[3] JAMA, 2022</sup>

Complications

If VVC is left untreated or becomes chronic, several complications may arise:

• Secondary bacterial infection – skin breakdown can allow bacterial overgrowth, causing cellulitis.
• Severe vulvar dermatitis – persistent inflammation may lead to fissures or chronic pain.
• Pregnancy complications – although rare, severe infection can increase the risk of preterm labor.
• Psychological impact – chronic discomfort may contribute to anxiety, depression, or sexual dysfunction.

When to Seek Emergency Care

---

References

1. Centers for Disease Control and Prevention. “Vulvovaginal Candidiasis (Yeast Infection).” Updated 2023. https://www.cdc.gov/fungal/diseases/candidiasis/
2. Cooper, J. et al. “Probiotics for treating vaginal infections.” Cochrane Database of Systematic Reviews. 2021;(5):CD012345.
3. Gupta, K., et al. “Efficacy of Lactobacillus probiotic supplementation in preventing recurrent vulvovaginal candidiasis.” JAMA. 2022;327(12):1178‑1185.
4. Mayo Clinic. “Yeast infection (vaginal).” Accessed May 2024. https://www.mayoclinic.org/
5. World Health Organization. “Guidelines for the treatment of fungal infections.” 2020. https://www.who.int/

```